A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor-Reference-Cited by-同舟云学术

A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor

Published:2015-04-22 Issue:284 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Klinghoffer Richard A.¹,Bahrami S. Bahram²,Hatton Beryl A.¹,Frazier Jason P.¹,Moreno-Gonzalez Alicia¹,Strand Andrew D.²,Kerwin William S.¹,Casalini Joseph R.¹,Thirstrup Derek J.¹,You Sheng¹,Morris Shelli M.¹,Watts Korashon L.¹,Veiseh Mandana²,Grenley Marc O.¹,Tretyak Ilona¹,Dey Joyoti¹,Carleton Michael¹,Beirne Emily¹,Pedro Kyle D.²,Ditzler Sally H.¹,Girard Emily J.²,Deckwerth Thomas L.¹,Bertout Jessica A.¹,Meleo Karri A.³,Filvaroff Ellen H.⁴,Chopra Rajesh⁵,Press Oliver W.²,Olson James M.²⁶⁷

Affiliation:

1. Presage Biosciences, Seattle, WA 98109, USA.

2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

3. Oncology Department, BluePearl Veterinary Partners, Seattle, WA 98125, USA.

4. Celgene Corporation, San Francisco, CA 94158, USA.

5. Celgene Corporation, Summit, NJ 07901, USA.

6. Department of Pediatrics, University of Washington, Seattle, WA 98195, USA.

7. Seattle Children’s Hospital, Seattle, WA 98105, USA.

Abstract

Simultaneous in vivo assessment of multiple cancer drugs and drug combinations using microinjection technology predicts systemic response in model tumors and has shown feasibility for assessment of drug efficacy in a pilot study in cancer patients.

Funder

NIH

NCI

Seattle Children's Hospital Neuro-Oncology Fund

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference36 articles.

1. Can the pharmaceutical industry reduce attrition rates?

2. The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities

3. Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs